{"entity":{"id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TUB-030 in small-cell lung cancer, non-small-cell lung cancer and triple-negative breast cancer, run by Tubulis GmbH, now recruiting.","summary":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06657222 by Tubulis GmbH, with 250 participants planned, started 2024-12-13 and due to reach its primary completion in 2028-12. Interventions recorded: TUB-030.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06657222","url":"https://clinicaltrials.gov/study/NCT06657222"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc","nsclc","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["tubulis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06657222","phase":"1/2","setting":"A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)","sponsor":"Tubulis GmbH","enrolled":250,"outcomes":[]},"route":"/trials/nct06657222/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/"}]}}